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Recent scientific advancements have greatly improved prenatal genetic testing 
technologies, which can now detect a wide array of genetic disorders at a high degree of 
accuracy. Down syndrome provides a unique context through which to analyze the effect of 
women’s access to prenatal genetic tests on test utilization and birth outcomes. In particular, 
typically only women of Advanced Maternal Age (AMA)—that is, women aged 35 and older—
have qualified for an amniocentesis, the most common prenatal diagnostic test for Down 
syndrome. Using Vital Statistics live birth data from 1989 to 2002, I exploit the arbitrary nature 
of this AMA amniocentesis eligibility cutoff by implementing a Regression Discontinuity (RD) 
design to quantify the effect of access to amniocentesis on amniocentesis use and birth outcomes. 
As a secondary component of my analysis, I explore whether the effect of access to 
amniocentesis shifted over the course of the 1990s, as alternative prenatal genetic tests for Down 
syndrome became available. I find that becoming eligible for an amniocentesis increased the 
probability a woman underwent an amniocentesis by 6.2 percentage points (or 62% relative to 
the mean take-up rate of women around the cutoff), but that the increase in amniocentesis take-
up at age 35 diminished significantly throughout the late 1990s. This negative time-trend in 
amniocentesis take-up at age 35 implies that over the latter half of my sample period, many 
amniocentesis-eligible women substituted away from amniocentesis and towards alternative 
prenatal genetic tests for Down syndrome that presented less risk to the fetus. Finally, I find no 
evidence that women terminated pregnancies that tested positive for Down syndrome or that test 
















Genetic disorders are surprisingly common, affecting an estimated 12 million Americans 
(PR Newswire, 2010). Recent scientific advancements—such as the “unlocking” of the human 
genome—have dramatically improved researchers’ understanding of genetic disorders. 
Importantly, one result of this scientific progress is improved prenatal genetic tests, which can 
detect genetic disorders at a high degree of accuracy and at a low risk to the fetus. Parents who 
undergo these prenatal genetic tests and learn that the fetus is affected by a genetic disorder may 
choose to terminate the pregnancy, or they may simply use this critical piece of information to 
better prepare for the type of care that their child will need after birth. The availability of these 
improved genetic testing technologies, then, has significant implications for families, and at a 
broader level, for the healthcare system as a whole. The use of these genetic tests—as well as 
any actions parents may take in response to the information provided to them by these tests—
impacts families’ healthcare expenditures, in terms of the types of healthcare services that 
families utilize and the magnitude of families’ spending on healthcare services. 
Overwhelmingly the most common chromosomal abnormality, Down syndrome is of 
particular interest. With a long and rich medical history that dates back to 1866, Down syndrome 
provides a powerful lens through which to explore the effects that the combination of (1) 
prenatal genetic testing technologies, and (2) recommendations for the use of these technologies, 
has had on women’s choices and behavior. In order to capture the causal effect of access to 
prenatal genetic tests for Down syndrome on women’s test utilization and their babies’ 
corresponding birth outcomes, I exploit the fact that expectant mothers have historically been 
offered differential access to prenatal diagnostic tests for Down syndrome, based on their age. In 
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particular, typically only women of Advanced Maternal Age (AMA)—that is, women aged 35 
and older—have qualified for an amniocentesis, the most common diagnostic test for Down 
syndrome. Critically, this AMA amniocentesis eligibility cutoff is (arguably) arbitrary, in the 
sense that there is not a “jump” in the probability that a woman has a child with Down syndrome 
at age 35. Utilizing the arbitrary construction of this cutoff, I implement a Regression 
Discontinuity (RD) design. Since the AMA amniocentesis eligibility threshold is arbitrary, 
women who are just of AMA should not be fundamentally different than women who are just too 
young to be labeled as AMA, which means that I can interpret any difference in amniocentesis 
take-up and Down syndrome incidence around the AMA threshold as the causal effect of 
amniocentesis eligibility. 
Using Vital Statistics birth data from 1989 to 2002, I investigate three specific questions. 
First, I explore whether there is an increase in amniocentesis take-up once women reach AMA. 
Second, I examine whether this increase—if it exists—diminishes over time. This second 
component of my empirical analysis is motivated by the fact that, over the course of the 1990s, 
new prenatal screening tests for Down syndrome were introduced. These screening tests, which 
typically only require a small sample of the mother’s blood, present substantially less risk to the 
fetus than an amniocentesis, and as a result, these new screening tests potentially made AMA 
women’s differential access to amniocentesis less important. To test this hypothesis, I investigate 
whether amniocentesis take-up at age 35 declines over the course of 1989 to 2002, as these new 
screening tests became more widely available to pregnant women. Lastly, I exploit the AMA 
amniocentesis eligibility cutoff to examine the effect of amniocentesis access on birth outcomes. 
In particular, I explore whether there is a shift in either Down syndrome incidence or broader 
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measures of infant health (i.e., the baby’s birth weight and five-minute Apgar score) at the AMA 
threshold.   
The rest of this paper is organized as follows. Section 1 provides background 
information, and Section 2 reviews the relevant medical and economic literature. Section 3 
describes the data, and Section 4 provides a graphical description of the data. Section 5 details 
my empirical strategy, Section 6 presents the main results, and Section 7 describes robustness 
checks and falsification tests. Finally, Section 8 concludes.  
 
Section 1: Background  
 
A Brief History of Down syndrome  
 
A familiar genetic condition, Down syndrome affects roughly one in every 700 babies 
born in the U.S. each year (Parker, et al., 2010). Individuals who have Down syndrome are easily 
recognizable and share distinct physical traits, including a flattened facial profile, poor muscle 
tone, and upward-slanting eyes. In addition to these obvious physical markers, individuals who 
have Down syndrome typically experience developmental delays, and they often require special 
education services (Bull, 2011, and Schieve, et al., 2009). Furthermore, children with Down 
syndrome face an increased risk of developing acute lymphoblastic leukemia (ALL) and myeloid 
leukemia (Stewart, 2009), and roughly half of all babies born with Down syndrome have a 
congenital heart defect (Bull, 2011). 
Even though Down syndrome undoubtedly predates the nineteenth century, Dr. John 
Langdon Down provided the first official documentation of Down syndrome in 1866.  In his 
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highly influential—but wildly offensive—“Observations on an Ethnic Classification of Idiots,” 
Down incorrectly attributes Down syndrome to “tuberculosis in the parents.” Furthermore, in a 
thinly-disguised and ethnically-motivated insult, Down argues that individuals who have Down 
syndrome must be of Mongolian descent. (Dr. Down considered Mongolians to be an inferior 
people) (Down, 1866).1 Constrained by nineteenth-century technological limits, Down’s essay 
essentially remained the only component of the Down syndrome medical literature until 1933, 
when it was observed that the probability that a woman has a child with Down syndrome 
increases with maternal age (Penrose, 1933). These surface-level observations formed the bulk of 
scientists’ understanding of Down syndrome until 1959, when Dr. Jérôme Lejeune discovered 
that Down syndrome is caused by a third copy of chromosome 21.  
Dr. Lejeune’s seminal breakthrough paved the way for a deeper understanding of Down 
syndrome. In particular, researchers quickly discovered that there are actually three types of 
Down syndrome: (1) Trisomy 21, (2) Translocation, and (3) Mosaicism. Consisting of 95% of all 
Down syndrome cases, Trisomy 21 is the most common form of Down syndrome, and in this 
type of Down syndrome, the extra copy of chromosome 21 attaches itself to the other two copies 
of chromosome 21. Translocation and mosaicism are substantially less prevalent than Trisomy 
21, and they make up approximately 3% and 2% of all Down syndrome cases, respectively 
(Shin, et al., 2011). In the case of mosaicism, only some cells have a third copy of chromosome 
21, meaning that individuals with mosaicism tend to display fewer characteristics associated with 
Down syndrome (Modi, et al., 2003). Interestingly, translocation is the only form of Down 
syndrome that is “inherited,” in the sense that it is caused by extra genetic material in either the 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 It was this hypothesis that led to individuals with Down syndrome being referred to as 
“Mongoloids” until the latter half of the twentieth century. 
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father or mother. With translocation, the extra copy of chromosome 21 attaches itself to a 
different pair of chromosomes (Fisher, 2013). 
 
Prenatal Diagnostic and Screening Tests for Down syndrome 
 
Sparked by Dr. Lejeune’s 1959 discovery, the past half-century has been marked by 
seemingly continuous discoveries and improvements of prenatal genetic tests for Down 
syndrome. Prenatal genetic tests for Down syndrome have been available since 1966, when Mark 
Steele and William Breg first discovered that an amniocentesis—which involves removing a 
sample of fluid from the amniotic sac—allowed for chromosomal karyotyping and in-utero 
diagnoses of Down syndrome (Steele and Breg, 1966). Considering the fact that an 
amniocentesis involves injecting a rather large needle through the wall of the uterus, it is perhaps 
unsurprising that an amniocentesis carries a relatively high risk of miscarriage, at around 0.6% 
(Mayo Clinic, 2015). Amniocentesis and Chorionic Villus Sampling (CVS)—a less common 
diagnostic test for Down syndrome—were the only available types of prenatal genetic tests for 
Down syndrome until the mid-1980s. 
Prenatal screening tests for Down syndrome were developed in the mid-1980s. In 
contrast to prenatal diagnostic tests for Down syndrome (like amniocentesis), prenatal screening 
tests for Down syndrome cannot definitively determine whether the fetus has Down syndrome. 
Rather, prenatal screening tests simply estimate the likelihood that the fetus has Down syndrome. 
Despite their lower degree of accuracy, screening tests offer one critical advantage over 
diagnostic tests: Unlike invasive diagnostic tests, screening tests for Down syndrome present 
effectively no risk to the fetus.  
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The first of these screening tests—simultaneously reported in 1984 by two different 
teams of researchers—measured a pregnant woman’s second-trimester alpha-fetoprotein (!FP) 
levels (Merkatz, et al., 1984, and Cuckle, et al., 1984).2 In 1988, the triple screen—which, in 
addition to measuring second-trimester maternal !FP levels, also measured second-trimester 
maternal unconjugated estriol (uE3) and human chorionic gonadotropin (HCG) levels3—was 
introduced (Wald, et al., 1988). Providing a more accurate risk assessment of the fetus’ 
likelihood of having Down syndrome than the !FP test (Wald, et al., 1988), the triple test forms 
the foundation of current Down syndrome screening tests (Reynolds, 2010).  
Two other notable prenatal screening tests for Down syndrome were discovered in the 
1990s. In 1992, Kypros Nicolaides, et al. first suggested that ultrasounds that measure the 
thickness of the fluid on the back on the fetus’ neck (fetal nuchal translucency, or FNT) could be 
used as a preliminary first-trimester screening test for Down syndrome (Nicolaides, et al., 1992). 
As the American College of Obstetricians and Gynecologists (ACOG) acknowledges, however, 
the first FNT tests faced several obstacles, namely that there was initially considerable variability 
in the test’s ability to detect Down syndrome (ACOG, 2007). The last breakthrough in prenatal 
screening for Down syndrome in the 1990s was the quadruple screen. Adding inhibin-A to the 
triple screen, Wald, et al., demonstrated that the quadruple screen had higher detection rates—
and importantly, lower false positive rates—than the triple screen (Wald, et al., 1996). Since 
1996, several new prenatal screening tests for Down syndrome have been introduced—including 
the integrated and stepwise sequential screens—but these new screening tests are essentially only 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 Both sets of researchers found a strong negative association between the level of !FP in the 
mother’s bloodstream during the second trimester and the probability that the fetus has Down 
syndrome. 
3 Wald, et al., found that maternal uE3 levels are depressed and that maternal HCG levels are 
elevated when the fetus has Down syndrome. 
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modifications to and expansions of the triple screen, quadruple screen, and FNT tests (ACOG, 
2007).  
In order to fully understand the potential impact that these new screening tests had on 
amniocentesis use, it is also imperative to understand whether pregnant women actually had 
access to these screening tests. Although data on screening take-up is limited, Glenn Palomaki, et 
al., analyzed laboratory data to determine (1) the total fraction of pregnancies screened for Down 
syndrome (excluding amniocentesis), and (2) the fraction of screened pregnancies that underwent 
each type of screening test, in 1988, 1992, 1995, 2011, and 2012. This data, compiled from five 
separate reports, is graphically depicted in Figures 1 and 2. 
 





























































Interestingly, Figure 1 shows that by as early as 1995, over 60% of pregnancies in the 
U.S. were being screened for Down syndrome. Considering that AMA women comprise between 
10% and 20% of total births in any given year, the fact that a solid majority of pregnancies were 
being screened for Down syndrome by the mid-1990s implies that many non-AMA women were 
undergoing these screening tests. Moreover, Figure 2 shows that by 1995, the triple test had 
become the dominant screening test for Down syndrome. Unfortunately, data on quadruple 
screen take-up is not available until 2011, but in 2011—15 years after the test was introduced—
the quadruple screen made up over 50% of that year’s screenings. Overall, these two figures 
paint a fascinating picture, and together they suggest that prenatal genetic screening tests for 
Down syndrome were becoming increasingly more accessible and popular throughout the 1990s.  
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Even though the available data clearly suggests that pregnant women were taking 
advantage of these screening tests for Down syndrome, the causal impact of these screening tests 
on amniocentesis use is theoretically ambiguous. On the one hand, it is possible that these less-
costly screening tests for Down syndrome served as “substitutes” for amniocentesis, particularly 
for AMA women. While Down syndrome screening tests are less accurate than an 
amniocentesis, AMA women may have replaced an amniocentesis with a screening test in order 
to minimize the risk presented to the fetus. In this case, one would expect the introduction of 
screening tests to decrease amniocentesis use among AMA women.  
On the other hand, perhaps amniocentesis and Down syndrome screening tests can be 
considered to be “complementary goods.” That is, it is possible that the widespread use of 
screening tests actually increased amniocentesis use among AMA women. Considering the fact 
that older mothers face a higher probability of giving birth to a child with Down syndrome, I 
would anticipate a greater fraction of AMA women’s screening results to indicate that the fetus 
likely has Down syndrome, relative to non-AMA women. If a “positive” screening test induced a 
new “type” of AMA woman to undergo an amniocentesis—namely, women who were concerned 
about an amniocentesis’ risks and would not have undergone an amniocentesis in the absence of 
a positive screening test result—this would potentially translate into a higher overall 
amniocentesis take-up rate for AMA women.4  In the “Main Results” sections of this paper, I 
will actually use the Vital Statistics birth data to empirically estimate the extent to which 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 While screening tests for Down syndrome provide an odds-ratio that estimates the likelihood 
that the fetus has Down syndrome, the results of these screening tests are then typically broken 
down into two categories: a “positive” result and a “negative” result. Women are typically told 
that the results of their screening test are positive if the odds of having a child with Down 
syndrome are determined to be greater than or equal to 1/270. Conversely, women are typically 
given a negative result if the odds of having a child with Down syndrome are calculated to be 
less than 1/270. 
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women’s prenatal genetic testing decisions shifted in response to the introduction of new 
screening tests for Down syndrome.  
 
Relevant Medical Guidelines for Prenatal Diagnostic Tests for Down syndrome 
 
The previous section of this paper emphasizes recent technological improvements in 
prenatal genetic tests for Down syndrome. While the available data on utilization of screening 
tests for Down syndrome suggests that screening tests were available to a large subset—if not the 
entire universe—of pregnant women, medical guidelines have limited women’s access to 
amniocentesis.  
The National Institute of Health (NIH) issued the first of these guidelines in 1978. Citing 
amniocentesis’ relatively high risk of miscarriage, the NIH stated that only AMA women should 
be able to undergo an amniocentesis5 (Wertz and Fletcher, 1978). Following the NIH’s lead, in 
1983, the ACOG and the American Academy of Pediatrics (AAP) published their first 
Guidelines for Perinatal Care. In this document, the ACOG and AAP reinforced 35 as the 
maternal “cutoff age” for amniocentesis eligibility (ACOG and AAP, 1983). These guidelines 
were informed by an influential paper written by Ernest Hook, et al., which calculates 35 as the 
age at which the probability of having a child with Down syndrome equals the risk of a 
miscarriage from an amniocentesis (Hook, et al., 1983). From an expected utility standpoint, this 
reasoning seems to suggest that 35 is the maternal age at which the expected utility “loss” from 
an amniocentesis-caused miscarriage equals the expected utility “gain” from avoiding having a 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
5 The NIH did establish several exceptions to this rule. For example, the NIH guidelines’ stated 
that non-AMA women who had already given birth to a child with a chromosomal abnormality 
(such as Down syndrome) were also eligible for an amniocentesis. 
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child with Down syndrome. Realistically, however, it is highly unlikely that expectant mothers 
place equal weight on these two potential outcomes. 
These two guidelines formed the backbone of physicians’ prenatal diagnostic testing 
recommendations until 2007. In 2007, the ACOG revised its 1983 recommendation, stating that, 
“All women—regardless of age—should have the option of invasive [diagnostic] testing” 
(ACOG, 2007).6 A comprehensive timeline of these medical guidelines, juxtaposed with 




6 The ACOG justified its decision to open up amniocentesis access to all women with the 
following paragraph: “A woman’s decision to have an amniocentesis or CVS is based on many 
factors, including the risk that the fetus will have a chromosomal abnormality, the risk of 
pregnancy loss from an invasive procedure, and the consequences of having an affected child if 
diagnostic testing is not done. Studies that have evaluated women’s preferences have shown that 
women weigh these potential outcomes differently. The decision to offer invasive testing should 
take into account these preferences and should not be solely age based” (ACOG, 2007). This 
statement seems to suggest that the ACOG recognized that, even though at age 35, the 
probability of having a child with Down syndrome equals the probability having an 
amniocentesis-caused miscarriage, the utility “gain” from avoiding a child with Down syndrome 
at age 35 likely does not equal the utility “loss” from a miscarriage at age 35. Unfortunately, the 


















































































Section 2: Previous Literature 
 
Perhaps unsurprisingly, the majority of the research that explores the effects of access to 
prenatal genetic tests for Down syndrome on women’s choices can be found in the medical 
literature. In their paper “The Impact of a New National Screening Policy for Down syndrome in 
Denmark,” Charlotte Ekelund, et al., report that a 2004 change in the Danish National Board of 
Health’s prenatal genetic testing guidelines—which required physicians to offer screening tests 
for Down syndrome to all pregnant women—reduced the number of invasive diagnostic 
procedures by just over 50%. Even more interestingly, the authors find that the incidence of 
Down syndrome births fell by roughly 40% after the introduction of the policy (Ekelund, et al., 
2008), which suggests that Danish women who underwent a screening test and received a 
positive result terminated the pregnancy.  
Sian Morgan, et al. examines the impact of a similar prenatal genetic testing policy 
change in the United Kingdom (UK). In 2003, the UK’s National Health Service (NHS) revised 
its “Model of Best Practice” to include a national screening policy for Down syndrome. In 
particular, this policy change opened up access to a first-trimester combined screening test for 
Down syndrome to all pregnant women.7 Analyzing data submitted by all of England’s 
cytogenetic laboratories from 2003 to 2011, Morgan, et al. report that 72% fewer invasive 
diagnostic tests were performed in 2011, relative to 2003 (Morgan, et al., 2013). Unfortunately, 
Morgan, et al. did not explore the impact of this new screening policy on Down syndrome 
incidence. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
7 A first-trimester combined screening test for Down syndrome includes an ultrasound that 
measures FNT, as well as a blood test that measures the levels of Pregnancy Associated Plasma 
Protein (PAPP-A) and free or total !-HCG in the mother’s blood.  
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Seeking to dissect the broad macro-level observations reported in the medical literature, 
the economics literature that investigates the effects of women’s access to prenatal genetic tests 
for Down syndrome primarily exploits older women’s differential access to amniocentesis. In 
France, for example, only pregnant women who are aged 38 or older (or women whose 
preliminary screening tests estimated that the probability the fetus has Down syndrome is greater 
than 0.04%) are eligible to be reimbursed for an amniocentesis through France’s national 
healthcare system. Capitalizing on this arbitrary reimbursement cutoff to implement a RD 
design, Christelle Garrouste, et al., find that qualifying for reimbursement increases the 
probability that a woman undergoes an amniocentesis by 55 percentage points. In other words, 
the authors find that pregnant women’s prenatal genetic testing decisions respond strongly to 
monetary incentives (Garrouste, et al., 2015).  
Eduardo Fajnzylber, et al. develop a dynamic model that uses expected utility theory to 
predict a woman’s “optimal” amniocentesis choice, based on her age and number of other 
children. Fajnzylber, et al. argue that the cost of an amniocentesis actually rises with maternal 
age, because in the case of an amniocentesis-caused miscarriage, it is harder for older women to 
“replace” a miscarriage with another pregnancy.  
The authors’ model generates two important predictions. First, a simple version of the 
authors’ model suggests that—if the probability of having a child with Down syndrome were 
constant over maternal age—the expected utility from an amniocentesis is actually higher for 
younger women than for older women. Second, a more flexible version of the authors’ model 
implies that amniocentesis rates, on average, should be higher for lower birth-order children, and 
that amniocentesis rates should decline as women reach the end of their reproductive period 
(Fahnzylber, et al., 2010).  
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Valerie Seror, however, claims that expected utility (EU) theory—which forms the basis 
of Fahnzylber, et al.’s model—is altogether a poor method for modeling a woman’s optimal 
amniocentesis choice. In EU theory, potential outcomes are linearly weighted by the probability 
that each potential outcome occurs. Seror claims that this linear weighting fails to reveal a 
woman’s optimal amniocentesis choice, because even though the probability of having a child 
with Down syndrome is incredibly low, the utility that a woman derives from a Down syndrome 
child is also quite low (or possibly negative). In particular, Seror questions EU theory’s ability to 
model individuals’ optimal choices when “all the probabilities associated with the outcomes are 
very high or very low…since the expected utilities of choice options are…highly insensitive to 
the utilities of outcomes.” In the case of Down syndrome, Seror argues that EU theory suggests 
that women would favor the choice of ‘no amniocentesis,’ even though the valuable information 
provided by an amniocentesis suggests that, in reality, this may not be the case (Seror, 2008).  
While not directly related to Down syndrome, Emily Oster, et al. find that individuals 
who are at-risk for Huntingdon’s disease (HD) and who learn that they carry the gene that causes 
HD are significantly more likely to purchase long-term care insurance than individuals who are 
at-risk for HD but who learn that they do not carry the HD gene. Oster, et al.’s results imply that 
genetic testing can play a critical role in shaping an individual’s healthcare decisions (Oster, et 
al., 2013).  
My analysis seeks to fill in the gaps that exist in the current literature. To the best of my 
knowledge, I will be the first to explore the effects of an amniocentesis eligibility cutoff on 
women’s choices and behavior in the U.S. Despite the fact that, for example, Ekelund, et al. find 
that the introduction of a national Down syndrome screening policy in Denmark significantly 
decreased both the number of invasive diagnostic procedures performed and the number of 
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babies born with Down syndrome, these results cannot easily be extrapolated to the U.S. After 
all, Denmark’s homogenous demographic make-up and national health insurance scheme stand 
in sharp contrast to the U.S.’ incredibly diverse population and private-market-driven healthcare 
system.  
Furthermore, the vast majority of the relevant literature—and in particular, the relevant 
medical literature—simply documents overall time trends in diagnostic testing take-up and 
Down syndrome incidence. By centering my empirical strategy on the AMA amniocentesis 
eligibility cutoff, in any given year, I will be able to observe the choices and birth outcomes of 
both (1) AMA women who were offered an amniocentesis, and (2) non-AMA women who were 
not offered an amniocentesis. By using this additional level of difference to implement a RD 
design, I will be able to observe much more than broad changes in amniocentesis use and Down 
syndrome incidence over time: Rather, I will actually be able to establish a causal relationship 
between amniocentesis eligibility and women’s amniocentesis take-up, and I will apply similar 
techniques to quantify the relationship between amniocentesis eligibility and corresponding birth 
outcomes.  
 
Section 3: Data  
 
To conduct my analysis, I utilize U.S. Vital Statistics live birth data from 1989 to 2002. 
Providing incredibly rich information on every documented U.S. live birth, Vital Statistics live 
birth data is publicly available through the Centers for Disease Control and Prevention (CDC). 
Over the course of 1989 to 2002, there were 60,137,858 recorded live births in the U.S. As will 
be explained in detail in the “Empirical Strategy” section of this paper, my analysis will focus 
only on first births, and in particular, on first births to mothers age 33 to 37, inclusive. Even 
! 20 
though I am limiting my sample to first births within a small neighborhood of the amniocentesis 
eligibility cutoff, the fact that the Vital Statistics data tracks the full universe of live births means 
that my preferred sample still captures the amniocentesis choices and birth outcomes of many 
AMA and non-AMA women.   
At its core, Vital Statistics birth data is simply a compilation of the information recorded 
in the U.S. Standard Certificate of Live Birth, which—as its name aptly suggests—is completed 
after each live birth. In addition to providing a wealth of information regarding the health status 
of the newborn, this certificate also records the mother’s prenatal care decisions and collects 
basic demographic information from both the mother and father. The period from 1989 to 2002 
corresponds to the use of the 1989 revision of the U.S. Standard Certificate of Live Birth.  
The 1989 revision of the U.S. Standard Certificate of Live Birth is the only version of the 
certificate that contains all of the information required for my empirical analysis. Critically, this 
version of the certificate records whether the baby has Down syndrome. Most importantly—and 
unlike previous or later versions of the certificate—the 1989 revision to the U.S. Standard 
Certificate of Live Birth explicitly asks mothers whether they underwent an amniocentesis. 
Given that my objective is to determine the effect that women’s differential access to 
amniocentesis has on women’s amniocentesis choices and subsequent birth outcomes, being able 
to track women’s amniocentesis decisions is essential to the successful execution of my 
empirical strategy.   
Table 1, which is given below, paints a basic descriptive picture of the mothers included 
in my dataset. In Column 1, the sample is restricted to first-time mothers who were between the 
ages of 33 and 37 (inclusive) at the time of the birth of their child (i.e., the sample is restricted to 
a two-year window around the AMA amniocentesis eligibility cutoff). As will be discussed in 
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more detail shortly, this restricted sample is my preferred sample for the remainder of my 
analysis, as comparing first-time mothers in a small neighborhood of the AMA amniocentesis 
eligibility cutoff will allow me to hone in on the causal effect of amniocentesis eligibility on 
amniocentesis take-up and birth outcomes.  
Table 1 highlights several important differences between the sample of all first-time 
mothers and my preferred sample. In addition to being more likely, on average, to undergo an 
amniocentesis and give birth to a baby with Down syndrome, the sample of 33-year-old to 37-
year-old first-time mothers were—perhaps unsurprisingly—substantially more likely to be 
married, to have a college degree, and to begin prenatal care in the first trimester. Moreover, the 
racial and ethnic composition differs substantially between the two samples: The fractions of 
Hispanic mothers and Hispanic fathers are nearly 50% smaller in my preferred sample, and the 
fraction of non-white mothers and fathers is also slightly smaller in the sample of 33-year-old to 
37-year-old first-time mothers.  
Table 1 also suggests that babies born to first-time mothers age 33 to 37 are, as a whole, 
less healthy than babies born to first-time mothers in my full sample. While the average linear 
five-minute Apgar score is nearly identical between the two samples, the probability that the 
baby’s five-minute Apgar score is less than seven is actually seven percent higher in my 
preferred sample. (Babies with a five-minute Apgar score of at least seven are typically 
considered to be in good health.) Furthermore, the probabilities that the baby is born at a low 
birth weight (<2,500 grams and ≥1,500 grams) or very low birth weight (<1,500 grams) are 
21% and 30% higher in my preferred sample, respectively. These statistics are not particularly 
surprising, however, given that older women’s pregnancies are, in general, riskier than younger 
women’s pregnancies (Kenny, et al., 2013).  
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Table 1, Summary Statistics: First-Time Mothers Age 33 to 37 vs. All First-Time Mothers 
(1989-2002 Combined) 
Standard deviations are given in parentheses. Each summary statistic except for father’s age can be interpreted as the 
fraction of mothers in that sample who possess that particular characteristic. 
 (1) 
First-Time Mothers Age 33 to 37  
(2)  
All First-Time Mothers  
(Age 18 to 45) 





























   
Began Prenatal Care in the First Trimester 0.9250 0.8456 
 (0.2634) (0.3613) 
Began Prenatal Care in the Second Trimester 0.0585 0.1228 
 (0.2347) (0.3282) 
Began Prenatal Care in the Third Trimester 0.0111 0.0230 
 (0.1046) (0.1498) 
Underwent an Ultrasound 0.6443 0.6253 
 (0.4787) (0.4840) 










 (0.2804) (0.3627) 
Married 0.8672 0.6714 
 (0.3393) (0.4697) 
Did Not Complete High School 0.0387 0.1437 
 (0.1929) (0.3508) 
Graduated High School 0.2029 0.3540 
 (0.4022) (0.4782) 
Completed Some College 0.2219 0.2363 
 (0.4155) (0.4248) 
Graduated College 0.5365 0.2659 
 (0.4987) (0.4418) 
Father’s Age 35.8749 28.577 
 (5.2211) (6.3986) 
Non-white Father 0.1437 0.1624 
 (0.3508) (0.3688) 
Hispanic Father 0.0751 0.1549 
 (0.2636) (0.3618) 
Sample Size 1,897,912 20,364,357 
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While not evident in Table 1, it is worth noting that there appears to be systematic 
underreporting of Down syndrome in the Vital Statistics data. In Figure 4, I have plotted the 
National Down Syndrome Society’s estimates of the likelihood that the fetus will have Down 
syndrome against the reported fraction of babies born with Down syndrome at each maternal 
age. (The probabilities provided by the National Down Syndrome Society are consistent to those 
presented in the medical literature.) Given that this gap between predicted and reported Down 
syndrome incidence is stable around age 35 (where the amniocentesis eligibility cutoff is 
located), this apparent underreporting of Down syndrome in the Vital Statistics data should not 
jeopardize the validity of my empirical analysis, but it is concerning nevertheless.  
There are several possible explanations for this gap. First, it may be the case that the 
estimates given in the medical literature are inaccurate. My background research suggests that 
these probabilities were calculated in the 1970s, when doctors and scientists—with the help of 
modern technology—were only first beginning to develop a detailed understanding of Down 
syndrome. Second, this apparent reporting gap may be reflective of women terminating 
pregnancies where a prenatal genetic test reveals that the fetus has Down syndrome. As I discuss 
in the “Main Results” section of this paper, however, I find no evidence that this is the case.    
Third, it is my understanding that the estimated probabilities of having a child with Down 
syndrome that are presented in the medical literature attempt to capture the underlying biological 
risk that the fetus will develop Down syndrome upon conception (i.e., that meiotic 
nondisjunction will occur). Since pregnancies in which the fetus develops Down syndrome have 
a substantially elevated risk for spontaneous termination, it is possible that a portion of this 
reporting gap in Down syndrome is due to the fact that some fetuses with Down syndrome 
spontaneously abort prior to birth (Morris, et al., 1999). Finally, it is possible that—at least in 
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some cases—Down syndrome may not be detected in time to be recorded on the birth certificate. 
Babies with Down syndrome typically suffer from other health problems (like congenital heart 
defects) that often require immediate care after birth. If doctors are primarily concerned with 
other health problems, they may not test for Down syndrome in time for it to be included in the 
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Section 4: Descriptive Results 
 
Before outlining my empirical strategy, I will first present graphical evidence that 
becoming eligible for an amniocentesis did—in fact—have a substantial impact on women’s 
prenatal testing decisions. In Figure 5, I plot the fraction of women who underwent an 
amniocentesis by maternal age over the combined period from 1989 to 2002. Displaying a sharp 
“jump” in amniocentesis take-up at age 35 (the amniocentesis eligibility cutoff) of around seven 
percentage points, Figure 5 provides strong evidence that there is a positive discontinuity in the 
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Instead of pooling all of the years in my sample together, Figure 6 graphs the fraction of 
women who underwent an amniocentesis by maternal age separately for each year from 1989 to 
2002. While there is a noticeable increase in the fraction of women who undergo an 
amniocentesis at age 35 in each year of the sample, the size of this discontinuity is monotonically 
decreasing over time. This clear downward trend in the fraction of women undergoing an 
amniocentesis at age 35 seems to suggest that amniocentesis-eligible women substituted away 
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Figure 7 depicts the fraction of babies born with Down syndrome by maternal age over 
the period from 1989 to 2002. Given that the probability of having a child with Down syndrome 
rises with maternal age, a noticeable decrease in Down syndrome incidence at age 35 would 
imply that a substantial fraction of women acted on their amniocentesis results by terminating 
pregnancies in which the fetus was revealed to have Down syndrome. Interestingly, however, in 
Figure 7, there is no apparent break in the fraction of babies born with Down syndrome at age 
35. It is important to note, however, that the lack of a readily-visible discontinuity in Down 
syndrome incidence at the AMA amniocentesis eligibility threshold is not enough to simply 
dismiss the possibility of a link between amniocentesis eligibility and Down syndrome 
incidence. Determining whether such a relationship exists will require a more thorough 
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Section 5: Empirical Strategy  
 
The sharp increase in amniocentesis take-up at the AMA amniocentesis eligibility 
threshold lends itself nicely to a Regression Discontinuity (RD) design. Explained simply, RD is 
an empirical method that can be used to estimate the causal effect of a treatment when access to 
the treatment is determined by an arbitrary cutoff. More formally, RD is typically an appropriate 
econometric technique when an individual only receives the treatment—or at the very least, only 
receives access to the treatment—when her value of an observed “assignment variable” (denoted 
here by !) exceeds that of some cutoff (denoted here by ").  
The intuition behind RD is easily digestible. If the cutoff that determines access to a 
treatment is entirely arbitrary and individuals cannot precisely manipulate the assignment 
variable !, then individuals whose value of ! was just high (or low) enough to qualify them for a 
particular treatment are likely not fundamentally different from individuals whose value of ! fell 
just short of the cutoff, except for the fact that individuals who qualified for the treatment 
actually received (or became eligible for) the treatment. If this is the case, then any variation in 
treatment status around the cutoff can be considered as good as randomly assigned. For a “sharp” 
RD—where the probability of receiving treatment jumps from 0 to 1 at the threshold "—this 
means that any variation in outcomes around the cutoff can be interpreted as the causal effect of 
the treatment.  
For my empirical analysis, I will employ a variant of a “fuzzy” RD design. Unlike a sharp 
RD, a fuzzy RD does not require treatment assignment to be a deterministic function of !. 
Instead, a fuzzy RD allows the discontinuity in the probability of treatment at the cutoff ! = " to 
be less than one. Formally, this discontinuity condition can be stated as:  
! 30 
 lim'↓) *+ ,- = 1 /!- = " + 1] ≠ / lim'↑) *+ ,- = 1 /!- = " + 1] 
 
where ,- is an indicator variable that equals one when an individual receives treatment and zero 
otherwise. 
I will use RD to exploit the fact that the amniocentesis eligibility threshold at age 35 is 
arbitrary. To calculate the causal effect of amniocentesis access on amniocentesis take-up and 
birth outcomes, I will effectively be comparing the amniocentesis use and birth outcomes of 
women just over the age of 35 (who were offered an amniocentesis) to women just under the age 
of 35 (who did not qualify for an amniocentesis).  
In order for RD to be an appropriate econometric technique, however, several conditions 
must hold. Perhaps most importantly, an RD design requires that individuals are unable to 
precisely manipulate the assignment variable !, which in this context is the mother’s age at the 
birth of her child. Considering that, as of 2013, 61.7% of women aged 15 to 44 were actively 
using some form of contraception, it is possible that some women delayed having children until 
they were at least 35, in order to ensure access to an amniocentesis (CDC, 2014). It is unlikely, 
however, that women were able to precisely manipulate their age at the birth of their child, 
particularly in the neighborhood of the AMA amniocentesis eligibility threshold. While modern 
contraceptives can be used to help avoid an unplanned pregnancy, it is highly unlikely that a 
woman will become pregnant immediately after she stops using contraceptives. Exactly when a 
woman will become pregnant after she stops using contraceptives is uncertain, and this 
uncertainty rises with maternal age (American Pregnancy Association, 2017).  
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Additionally, in order for women near the AMA amniocentesis eligibility threshold to 
even have had an incentive to precisely manipulate the age at which they gave birth, it must be 
the case that women were aware of the AMA amniocentesis eligibility cutoff before they became 
pregnant. While the AMA amniocentesis eligibility cutoff was a nationally adopted practice, it 
was not explicitly publicized to women who were contemplating becoming pregnant, building 
my confidence in my assumption that there is not differential sorting across the AMA 
amniocentesis eligibility threshold. As a cautionary step, however, I limit my analysis to first-
time mothers, as first-time mothers were likely the least aware of the AMA eligibility cutoff 
prior to becoming pregnant.8   
To empirically test whether there is differential sorting across the AMA threshold, I 
conducted “placebo RDs” on several covariates that were determined prior to treatment 
assignment, such as the mother and father’s race and ethnicity. In Figure 8, I plot the mean value 
of these characteristics by maternal age for all first-time mothers over the entire period from 
1989 to 2002. Reassuringly, there does not appear to be a “jump” in any of these baseline 
characteristics at the AMA amniocentesis eligibility cutoff, increasing my confidence that the 
only systematic difference between AMA women and non-AMA women is amniocentesis 
eligibility. To ensure that these results were not solely a function of convenient scaling of my y-
axes, I also estimated equation (1) (described below) separately for each baseline characteristic 
over the period from 1989-2002 combined, using the baseline characteristic as the dependent 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
8 While not featured in this paper, I also repeated my analysis with second-births, and my results 
were broadly consistent with my results from my analysis of first-births. 
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variable. Consistent with the pictures painted in Figure 8, the results from this set of regressions 





















9!While several of the regression coefficients of interest are statistically significant at the five 
percent level, the point estimates are quite small relative to the mean, arguably rendering these 
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Lastly, in order for an RD design to be an appropriate empirical design, it must also be 
true that there are no other relevant changes at age 35 that could influence amniocentesis take-up 
or birth outcomes (or both). To the best of my knowledge, no other medical procedures or 
guidelines employ 35 as an eligibility cutoff. Furthermore, even though the probability that a 
woman will have a child with Down syndrome increases with maternal age, this increase is 
continuous and gently rolls across the AMA threshold, suggesting that there is not a sudden 
biological difference between AMA and non-AMA women located close to the amniocentesis 
eligibility threshold. As the blue line in Figure 4 shows, the medical literature’s estimates of the 
probability of having a child with Down syndrome does not suddenly increase at the age of 35. 
(Figure 4 is displayed in the “Data” section of this paper.)  
 To actually implement an RD design and quantify the discontinuity in amniocentesis 
take-up at the AMA eligibility cutoff, I estimate local linear regressions. The basic regression 
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(1)!5-6 = 7 + 89: !-6 − 35 ≥ 0 + @ !-6 − 35 + A !-6 − 35 ∗ : !-6 − 35 ≥ 0 +C-6DE + 1-6 
 
where 5-6 is an indicator variable that equals one if woman i undergoes an amniocentesis in year 
t, !-6 is woman i’s age at the birth of her child, : !-6 − 35 ≥ 0  is an indicator variable that 
equals one when a woman is 35 or older (and therefore qualifies for an amniocentesis), !-6 − 35  is a linear function (centered at age 35) that describes the relationship between a 
woman’s age at birth and the probability that she undergoes an amniocentesis, and C-6 is a 
vector of other controls.10 (For the remainder of the paper, I will refer to the variable : !-6 − 35 ≥ 0  simply as AMA.) Normalizing the assignment variable to zero at the cutoff " =35 allows me to interpret 89 as the size of the discontinuity in amniocentesis use at age 35, and 
the interaction term !-6 − 35 ∗ : !-6 − 35 ≥ 0  allows the relationship between maternal age 
and amniocentesis use to differ on both sides of the cutoff.  
Since equation (1) is a local linear regression, my first challenge was to select the 
“optimal” bandwidth for the regression. At its core, the bandwidth selection problem boils down 
to a tradeoff between precision and bias. On the one hand, a narrow bandwidth ensures that a line 
will be a better approximation for the underlying relationship between the assignment variable 
and the outcome variable, but a narrow bandwidth utilizes observations from only a small 
portion of the overall sample, reducing the precision of the estimates. Conversely, a wide 
bandwidth will provide more precise estimates, but it will also likely be more biased, as a line 
will probably be a poor fit for data far away from the cutoff.   
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
10 It is worth noting that a sharp RD is just a special case of a fuzzy RD, where 89 = 1 and all 
other regression coefficients equal zero.  
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 I calculated the “optimal” bandwidth for my local linear regression by following the 
procedure recommended by Guido Imbens and Karthik Kalyanaraman (Imbens and 
Kalyanaraman, 2012). When applied to my dataset, the Imbens and Kalyanaraman (IK) 
bandwidth selection method recommends a bandwidth of approximately 1.09.11 Unfortunately, 
my assignment variable—a woman’s age at the birth of her child—is discrete, in the sense the 
Vital Statistics birth data measures maternal age in one-year intervals. This “lumping” of the 
assignment variable renders it impossible for me to utilize a bandwidth of exactly 1.09. As a 
result, my preferred bandwidth is two, and the results presented in the body of this paper will 
feature regressions implemented with a bandwidth of two. Importantly, however, my results are 
qualitatively consistent with a host of bandwidths, ranging from three to ten, and these 
alternative sets of results are given in the “Robustness Checks and Falsification Tests” section of 
the paper.   
I first estimate equation (1) with a bandwidth of two around the AMA threshold over the 
entire period from 1989 to 2002, in order to calculate the “average” effect of amniocentesis 
eligibility on amniocentesis take-up. (My regression estimations with a bandwidth of two only 
include first-time mothers age 33 to 37, inclusive.) Then, in order to track whether the size of the 
discontinuity in amniocentesis use at the AMA threshold varied over time with the introduction 
of screening tests for Down syndrome, I estimate equation (1) separately for each of the years 
from 1989 to 2002.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
11 While I was unable to estimate the optimal bandwidth using my full sample, the optimal 
bandwidth for a 20% random sample of my data was 1.09. Furthermore, when I estimated the 
optimal bandwidth for each year from 1989 to 2002, the range of optimal bandwidths was 1.22 to 
1.37, providing me with more confidence that the optimal bandwidth for my full sample would 
be between one and two.  
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After quantifying the effect of amniocentesis eligibility on amniocentesis use, I explore 
whether there is a corresponding discontinuity in Down syndrome incidence at the AMA 
threshold. That is, I directly estimate the effect of amniocentesis eligibility on Down syndrome 
incidence. Also estimated using a bandwidth of two years, this “reduced form” regression model 
is given as follows:  
 
(2)!FG-6 = 7 + 8HI: !-6 − 35 ≥ 0 + @ !-6 − 35 + A !-6 − 35 ∗ : !-6 − 35 ≥ 0 +C-6DE + 1- 
 
where FG-6 is an indicator variable that equals one if woman i’s child has Down syndrome. (All 
other variables and subscripts are identical to those in equation (1).) Similar to equation (1), 8HI 
is my coefficient of interest. Considering the estimated biological probability of having a child 
with Down syndrome rises with maternal age (see Figure 4), if a substantial fraction of women 
who underwent an amniocentesis terminated pregnancies where the fetus tested positive for 
Down syndrome, I would expect the estimated coefficient 8HI to be negative. My main results 
are given in the next section.  
 
Section 6: Main Results 
 
 
The Effect of Amniocentesis Eligibility on Amniocentesis Take-Up 
 
 
 Table 2 presents the results from the implementation of regression equation (1) with a 
bandwidth of two (that is, using first-time mothers age 33 to 37), for all my data years (1989-
2002) combined. Column 1 does not include any controls, and Column 2 includes controls for a 
vector of seven maternal and paternal baseline characteristics. Reassuringly, the point estimate of 
interest (the estimated coefficient on AMA) is robust to the inclusion of these controls, providing 
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additional evidence that there was not differential sorting across the AMA amniocentesis 
eligibility threshold. The estimated coefficient on AMA in Column 2 of Table 2 implies that the 
probability a woman underwent an amniocentesis increased by 6.17 percentage points at the 
AMA amniocentesis eligibility threshold, a 62% increase over the mean amniocentesis take-up 
rate for 33 to 37 year-olds, and a staggering 239% increase over the mean amniocentesis take-up 
for the entire sample of first-time mothers. This coefficient—which is my key coefficient on 
interest—is statistically significant at the one-percent level. Since in Table 2, equation (1) was 
estimated using all of my data years combined, the estimated coefficients on AMA can be 
interpreted as the average effect of amniocentesis eligibility on amniocentesis take-up across my 
entire sample period (1989-2002). 
In Column 3, I add year fixed effects, and in Column 4, I add an indicator variable that 
equals one if the year is at least 1996, and I interact this dummy variable with AMA, Age – 35, 
and (Age – 35)*AMA. In 1996, the quadruple screen was introduced, and it was arguably the 
most important new prenatal screening test introduced over my sample period (1989-2002). (The 
quadruple screen was still the most popular screening test for Down syndrome in 2011, the latest 
year for which information on screening test take-up is available (Palomaki, et al., 2013).)  
Moreover, as seen in Figure 1, the use of all screening tests (including the previously-introduced 
triple screen) increased dramatically in the early 1990s, suggesting that the use of amniocentesis 
might have been different in the first and second half of this decade. Thus, the interaction term 
between Post-1996 and AMA provides a rough estimate of the extent to which AMA women’s 
amniocentesis testing decisions changed in response to the introduction of new screening tests 
for Down syndrome.  
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As I briefly discussed in the “Background” section of this paper, the effect of the 
availability of these new screening tests on amniocentesis take-up is theoretically ambiguous. On 
the one hand, unlike an amniocentesis, screening tests for Down syndrome present essentially 
zero risk to the fetus, and this reduction in risk may have led AMA women to substitute away 
from amniocentesis as new prenatal screening tests became available. On the other hand, it is 
possible that the introduction of screening tests actually increased amniocentesis use among 
AMA women. That is, these new screening tests may have induced a new “type” of woman to 
undergo an amniocentesis—namely, women who were concerned about the risks surrounding an 
amniocentesis and only underwent an amniocentesis because they received a positive result on a 
screening test for Down syndrome. My results are consistent with the first story, as the point 
estimate on Post-1996*AMA implies that 35-year-old women who gave birth to their first child 
in 1996 or later were one percentage point (or 10%) less likely to undergo an amniocentesis than 


















Table 2, The Effect of Amniocentesis Eligibility on Amniocentesis Take-Up,  
All Years (1989-2002 Combined) 
The dependent variable is an indicator variable that equals one if the mother underwent an amniocentesis. All 
regressions were estimated using a bandwidth of two (i.e., only first-time mothers ages 33 to 37 (inclusive) were 
included in the sample). AMA is an indicator variable that equals one if the mother was at least age 35 at the birth of 
her child, and Post-1996 is an indicator variable that equals one if the year is at least 1996. Standard errors are 
clustered by mother’s age, and standard errors are given in parentheses. 
*p < 0.10, **p < 0.05, ***p < 0.01 
 (1) (2) (3) (4)  
     
AMA 0.0619*** 0.0617*** 0.0620*** 0.0680*** 
 (0.0018) (0.0018) (0.0018) (0.0020) 
Age – 35  0.0237*** 0.0228*** 0.0229*** 0.0329*** 
 (0.0000) (0.0001) (0.0001) (0.0002) 
(Age – 35)*AMA -0.0020 -0.0019 -0.0016 -0.0097*** 
 (0.0015) (0.0015) (0.0015) (0.0018) 
Post-1996  
 




  -0.0100*** 
(0.0005) 
(Post-1996)*(Age – 35)   
 
  -0.0184*** 
(0.0001) 
(Post-1996)*(Age – 35)*AMA  
 
  0.0154*** 
(0.0005) 
Non-white Mother  -0.0123** -0.0096* -0.0096* 
  (0.0044) (0.0038) (0.0038) 
Hispanic Mother  -0.0176** -0.0137** -0.0137** 
  (0.0057) (0.0047) (0.0047) 
Mother Did Not Complete High School  -0.0238* -0.0247* -0.0248* 
  (0.0095) (0.0100) (0.0100) 
Mother Completed Some College  0.0134** 0.0149** 0.0147** 
  (0.0047) (0.0049) (0.0049) 
Mother Graduated College  0.0337** 0.0382** 0.0377** 
  (0.0093) (0.0100) (0.0101) 
Mother is Married  -0.0057*** -0.0056*** -0.0055*** 
  (0.0009) (0.0007) (0.0007) 
Father’s Age  0.0011*** 0.0012*** 0.0012*** 
  (0.0002) (0.0002) (0.0002) 
Non-white Father  -0.0195** -0.0193** -0.0193** 
  (0.0053) (0.0052) (0.0052) 
Hispanic Father  -0.0178** -0.0157** -0.0158** 
  (0.0053) (0.0047) (0.0047) 
Constant 0.0813*** 0.0326** 0.0588*** 0.0640*** 
 (0.0000) (0.0088) (0.0025) (0.0086) 
Year Fixed Effects No No  Yes Yes 
Mean of Dependent Variable 0.0990 0.0990 0.0990 0.0990 
N 1,679,707 1,679,707 1,679,707 1,679,707 
R2 0.0404 0.0462 0.0531 0.0544 
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To more precisely estimate the extent to which the discontinuity in amniocentesis take-up 
at the AMA threshold evolved over my sample period, I next estimate equation (1) separately for 
each data year from 1989 to 2002.  Since the amniocentesis eligibility cutoff remained at 35 over 
my entire sample period, any decline in amniocentesis take-up at age 35 is likely caused by 
women substituting away from amniocentesis and towards prenatal screening tests for Down 
syndrome.  
In each of the regression estimations, I include the same vector of controls seen in Table 
2, and I restrict the bandwidth to two. Table 3 presents the results from these regressions, and the 89’s (the point estimates of interest) are depicted graphically in Figure 9.   
 Although the point estimates on AMA bounce around in magnitude from 1989 to the mid 
1990s, the size of the estimated discontinuity in amniocentesis take-up at the AMA threshold 
begins to shrink in the late 1990s, and this downward trend continues until 2002, the final year in 
my dataset. In 1989, for example, my results suggest that the probability a woman underwent an 
amniocentesis increased by 6.84 percentage points at the amniocentesis eligibility cutoff, but the 
size of this discontinuity had shrunk to 4.35 percentage points by 2002, a 36% decline. This 







Table 3, The Effect of Amniocentesis Eligibility on Amniocentesis Take-Up, Estimated Separately for 1989-2002 
The dependent variable is an indicator variable that equals one if the mother underwent an amniocentesis. All regressions were estimated using a bandwidth of 
two (i.e., only first-time mothers ages 33 to 37 (inclusive) were included in the sample). All regressions include controls for the mother and father’s race and 
ethnicity, the mother’s marital status, and the mother’s educational attainment. AMA is an indicator variable that equals one if the mother was at least 35 at 
the birth of her child. Standard errors are clustered by mother’s age, and standard errors are given in parentheses. 















        
AMA 0.0684*** 0.0561*** 0.0656*** 0.0620*** 0.0696*** 0.0686*** 0.0803*** 
 (0.0015) (0.0011) (0.0033) (0.0022) (0.0022) (0.0012) (0.0026) 
Age – 35  0.0382*** 0.0392*** 0.0360*** 0.0390*** 0.0323*** 0.0294*** 0.0228*** 
 (0.0001) (0.0002) (0.0001) (0.0003) (0.0002) (0.0001) (0.0001) 
(Age – 35)*AMA -0.0164*** -0.0167*** -0.0156*** -0.0160*** -0.0063** -0.0009 -0.0019 
 (0.0014) (0.0010) (0.0030) (0.0019) (0.0019) (0.0011) (0.0023) 
Constant 0.0833*** 0.0768*** 0.0810*** 0.0751*** 0.0674*** 0.0710*** 0.0558*** 
 (0.0059) (0.0131) (0.0079) (0.0145) (0.0101) (0.0042) (0.0071) 
Controls Yes Yes Yes Yes Yes Yes Yes 
        
Mean of Dependent Variable 0.1083 0.1281 0.1238 0.1228 0.1200 0.1130 0.1083 
N 83,893 93,752 101,444 108,474 112,122 119,393 121,624 















        
AMA 0.0707*** 0.0759*** 0.0632*** 0.0603*** 0.0502*** 0.0456*** 0.0435*** 
 (0.0012) (0.0017) (0.0007) (0.0008) (0.0019) (0.0018) (0.0025) 
Age – 35  0.0232*** 0.0157*** 0.0160*** 0.0146*** 0.0142*** 0.0123*** 0.0101*** 
 (0.0002) (0.0002) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
(Age – 35)*AMA 0.0042** 0.0060** 0.0069*** 0.0082*** 0.0030 0.0056** 0.0067** 
 (0.0011) (0.0014) (0.0007) (0.0006) (0.0017) (0.0015) (0.0021) 
Constant 0.0555*** 0.0255** 0.0198* 0.0173 0.0155 0.0199* 0.0129 
 (0.0112) (0.0092) (0.0091) (0.0107) (0.0113) (0.0076) (0.0098) 
Controls Yes Yes Yes Yes Yes Yes Yes 
        
Mean of Dependent Variable 0.1069 0.0986 0.0891 0.0836 0.0740 0.0659 0.0575 
N 126,503 130,198 132,951 133,656 138,893 140,670 145,509 
R2 0.0551 0.0480 0.0435 0.0411 0.0333 0.0313 0.0295 
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Figure 9  








































The Effect of Amniocentesis Eligibility on Amniocentesis Take-Up, 
Estimated Separately for 1989-2002
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Interpreted at its most simplistic level, this significant decrease in the size of the 
discontinuity in amniocentesis take-up at the AMA threshold over the course of 1989-2002 
appears to imply that, on net, amniocentesis and prenatal screening tests for Down syndrome are 
substitute goods. While—unlike an amniocentesis—a prenatal screening test provides imperfect 
information (in the sense that it only estimates the likelihood that the fetus has Down syndrome), 
the fact that prenatal screening tests typically only require an ultrasound or sample of the 
mother’s blood means that screening tests present essentially zero risk to the fetus. Given that an 
amniocentesis is arguably costlier for older women (it more difficult for older women to 
“replace” an amniocentesis-caused miscarriage with another pregnancy), this reduction in risk 
appears to have induced a significant fraction of women at the AMA amniocentesis eligibility 
cutoff to forgo an amniocentesis, and to rely instead only on the information provided by 
prenatal screening tests for Down syndrome.  
 
The Effect of Amniocentesis Eligibility on Down syndrome Incidence  
 
 I next explore whether there is a noticeable discontinuity in Down syndrome incidence at 
the amniocentesis eligibility threshold to match the significant increase in amniocentesis take-up 
that I observe at age 35. Since an amniocentesis is typically performed early in the second 
trimester of pregnancy, one important way women could act on a positive amniocentesis result is 
by terminating the pregnancy. As I touched upon in the “Empirical Strategy” section of this 
paper, if a substantial fraction of women who undergo an amniocentesis and learn that the fetus 
has Down syndrome choose to terminate the pregnancy, this would likely be reflected in a 
sizeable decrease in Down syndrome incidence at the amniocentesis eligibility threshold.  
! 47 
 To econometrically estimate whether there is a shift in Down syndrome incidence at the 
amniocentesis eligibility threshold, I estimate equation (2) for the years 1989 to 2002 combined. 
Table 4 presents the results from these regressions. Identical in setup up to Table 2, Column 1 of 
Table 4 includes no additional controls, and Column 2 includes controls for a host of baseline 
maternal and paternal characteristics, such as the mother and father’s race and ethnicity and the 
mother’s educational attainment. Consistent with Figure 7, Columns 1 and 2 in Table 4 provide 
no evidence that there is a significant shift in Down syndrome incidence at the AMA 
amniocentesis eligibility threshold. In fact, the estimated coefficient on AMA in Column 2 of 
Table 4 suggests that, over the entire sample period, the probability of having a child with Down 
syndrome increased by 0.004 percentage points at the amniocentesis eligibility threshold. (This 
result is not statistically significant at conventional levels.)  
 Like Column 4 in Table 2, Column 4 in Table 4 includes an indicator variable that equals 
one if the year is at least 1996 (the year in which the quadruple screen was introduced), as well 
as interactions between this indicator variable (Post-1996) and AMA, Age – 35, and (Age – 
35)*AMA. Since the results presented in Table 3 and Figure 9 provide strong evidence that 
women began to substitute away from an amniocentesis in the mid-1990s, if the results of an 
amniocentesis had a substantial impact on women’s behavior or the informational value of an 
amniocentesis changed over this time period, one may expect to see a differential shift in the 
effect of amniocentesis eligibility on Down syndrome incidence in the post-1996 period. 




12 Ideally, I would also estimate equation (2) separately for each year in my sample, as I do for 
amniocentesis use, but the rarity of Down syndrome means that I lack the statistical power to 
precisely do so. 
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Table 4, The Effect of Amniocentesis Eligibility on Down syndrome Incidence, All Years  
(1989-2002 Combined)  
The dependent variable is an indicator variable that equals one if Down syndrome was reported on the birth 
certificate. All regressions were estimated using a bandwidth of two (i.e., only women ages 33 to 37 (inclusive) were 
included in the sample). AMA is an indicator variable that equals one if the mother was at least age 35 at the birth of 
her child, and Post-1996 is an indicator variable that equals one if the year is at least 1996. Standard errors are 
clustered by mother’s age, and standard errors are given in parentheses. 
*p < 0.10, **p < 0.05, ***p < 0.01 
 (1) (2)  (3) (4)  
     
AMA 0.00005 0.00004 0.00004 0.00005 
 (0.00002) (0.00002) (0.00002) (0.00003) 
Age – 35  0.00003*** 0.00004*** 0.00004*** -0.00003*** 
 (0.00000) (0.00000) (0.00000) (0.00000) 
(Age – 35)*AMA 0.00003 0.00003 0.00003 0.00008** 
 (0.00002) (0.00002) (0.00002) (0.00002) 
Post-1996  
 




  -0.00001 
(0.00001) 
(Post-1996)*(Age – 35)   
 
  0.00012*** 
(0.00000) 
(Post-1996)*(Age – 35)*AMA  
 
  -0.00009*** 
(0.00001) 
Non-white Mother  -0.00015* -0.00014* -0.00014* 
  (0.00006) (0.00006) (0.00006) 
Hispanic Mother  -0.00019 -0.00018 -0.00018 
  (0.00016) (0.00016) (0.00016) 
Mother Did Not Complete High School  0.00002 0.00002 0.00002 
  (0.00007) (0.00007) (0.00007) 
Mother Completed Some College  -0.00010 -0.00010 -0.00010 
  (0.00005) (0.00005) (0.00005) 
Mother Graduated College  -0.00021** -0.00020** -0.00020** 
  (0.00007) (0.00007) (0.00007) 
Mother is Married  0.00002 0.00002 0.00002 
  (0.00008) (0.00008) (0.00008) 
Father’s Age  -0.00001 -0.00001 -0.00001 
  (0.00000) (0.00000) (0.00000) 
Non-white Father  -0.00016 -0.00016 -0.00016 
  (0.00008) (0.00008) (0.00008) 
Hispanic Father  -0.00012 -0.00012 -0.00012 
  (0.00010) (0.00010) (0.00010) 
Constant 0.00058*** 0.00103*** 0.00130*** 0.00125*** 
 (0.00000) (0.00011) (0.00019) (0.00016) 
Year Fixed Effects No No Yes Yes  
Mean of Dependent Variable 0.0006 0.0006 0.0006 0.0006 
N 1,606,152 1,606,152 1,606,152 1,606,152 
R2 0.00001 0.00005 0.00006 0.00007 
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It is important to acknowledge, however, that the lack of a statistically meaningful 
relationship between amniocentesis eligibility and Down syndrome incidence may be partially 
due to a lack of statistical power. After all, Down syndrome is a rare genetic condition, and 
Figure 4 suggests that there is systematic underreporting of Down syndrome in the Vital 
Statistics data.  The rarity of Down syndrome—combined with underreporting and the fact that 
amniocentesis take-up is far less than 100% at the eligibility threshold—may simply mean that 
my empirical strategy would not be able to detect a link between amniocentesis eligibility and 
Down syndrome incidence, even if such a link existed.  
Furthermore, Vital Statistics birth data is not the optimal dataset with which to explore 
whether there are “missing children” with Down syndrome at the amniocentesis eligibility 
cutoff, since Vital Statistics birth data only captures the prenatal genetic testing choices and birth 
outcomes of babies who were actually born. Ideally, to determine the extent to which women 
terminated pregnancies where an amniocentesis reveals that the fetus has Down syndrome, I 
would analyze data that described every pregnancy in the U.S. over the period from 1989 to 
2002. Unfortunately, such a dataset does not (yet) exist.  
In an effort to address these limitations, I implement an alternative regression 
specification that estimates the effect of amniocentesis eligibility on the number of first births for 
my sample period of 1989 to 2002. This alternative specification requires me to aggregate my 
dataset to the maternal age-year level, and as a result, this regression specification may be better 
able to capture any shifts in the overall birth distribution at age 35.  (A dip or “hollowing out” in 
the birth distribution at age 35 would be consistent with women terminating pregnancies that test 
positive for Down syndrome.) To implement this alternative specification, I estimate equation (2) 
at the maternal age-year level, changing the dependent variable to be the number of first births. 
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In Figure 10, I plot the distribution of first-born babies for the period from 1989 to 2002, 
combined.  
Collapsing my data to the maternal age-year level reduces my total number of 
observations to 590, and as a result of this dramatic drop in sample size, I do not implement a 
local linear regression with a bandwidth of two. Instead, I estimate a local linear regression with 
a bandwidth of five. (That is, I restrict my sample to maternal ages between 30 and 40, 
inclusive.) I provide my results from my estimation of this alternative regression specification in 
Table 5. Similar in setup to Table 4, in Column 3 of Table 5, I add year fixed effects, and in 
Column 4, I add an indicator variable that equals one if the year is at least 1996 (the year in 
which the quadruple screen was introduced), and I interact this variable (Post-1996) with AMA, 
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Table 5, The Effect of Amniocentesis Eligibility on the Number of First Births,  



























The dependent variable is the number of first births. The regressions in all three columns were estimated using a 
bandwidth of five (i.e., only first-time mothers age 30 to 40 (inclusive) were included in the sample). AMA is an 
indicator variable that equals one if the mother was at least age 35 at the birth of her child, and Post-1996 is an 
indicator variable that equals one if the year is at least 1996. Data is collapsed at the maternal age-year level. 
Standard errors are clustered by mother’s age, and standard errors are given in parentheses. 
*p < 0.10, **p < 0.05, ***p < 0.01 
 
The results presented in Table 5 are broadly consistent with the results presented in Table 
4, and they provide no evidence that women are terminating pregnancies that test positive for 
Down syndrome. The point estimates on AMA in Columns 1 and 2 are positive, implying that the 
number of first births actually increased at age 35. This result is the exact opposite of what I 
would expect to see if a substantial fraction of women at the AMA threshold who underwent an 
amniocentesis and learned that the fetus had Down syndrome terminated the pregnancy. (If a 
substantial fraction of women at the AMA threshold terminated pregnancies that tested positive 
for Down syndrome, I would expect to see a “hollowing out” or “dip” in the birth distribution at 




    
AMA 3395.88** 3395.88* 3957.16* 
 (1517.38) (1587.74) (1961.93) 
Age – 35  -9221.86*** -9221.86*** -9597.79*** 
 (343.99) (359.94) (491.81) 
(Age – 35)*AMA 5125.52*** 5125.52*** 5807.66*** 
 (441.36) (461.83) (581.66) 
Post-1996   11876.50*** 
   (1177.70) 
Post-1996*AMA   -1122.57 
   (814.17) 
(Post-1996)*(Age – 35)    751.86** 
   (279.24) 
(Post-1996)*(Age – 35)*AMA   -1364.27*** 
   (282.22) 
Constant 21934.24*** 16946.63*** 15710.28*** 
 (1285.23) (1414.61) (1807.05) 
Year Fixed Effects No Yes Yes 
    
Mean of Dependent Variable 30,776 30,776 30,776 
N 154 154 154 
R-squared 0.9766 0.9945 0.9952 
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age 35; Figure 10 also provides no visual evidence of such a dip.) Furthermore, while the point 
estimate on (Post-1996)*AMA is negative, it is statistically insignificant at conventional levels, 
indicating that there was not a differential shift in the number of first births to AMA women in 
the pre-1996 and post-1996 periods.  
Lastly, returning to my primary analysis sample of all births to first-time mothers 
between the ages of 33 and 37, I investigate whether there is a discontinuity in any broader 
measures of infant health at the amniocentesis eligibility cutoff. In particular, I explore whether 
there is a discontinuity in the probability that the baby is born with any chromosomal 
abnormality, the probability that the baby is born at a low birth weight (less than 2,500 grams 
and greater than or equal to 1,500 grams), the probability that the baby is born at a very low birth 
weight (less than 1,500 grams), the baby’s 5-minute Apgar score, and the probability that the 
baby has a five-minute Apgar score less than seven at age 35.13 (As mentioned in the “Data” 
section of this paper, babies with Apgar scores of at least seven are generally considered to be in 
good health.) 
Table 6 reports the results from this set of regressions. Using each of these five measures 
of infant health as the dependent variable, I estimate equation (2) within a two-year bandwidth of  
the amniocentesis eligibility threshold. I fail to detect improvements in any of these infant health 
outcomes at the amniocentesis eligibility threshold. The results in Table 6 actually suggest that 
(1) the probability the baby has any chromosomal abnormality or neural tube defect, (2) the 
probability the baby is born at a low birth weight, and (3) the probability that the baby’s five-
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
13 While amniocentesis is primarily used to detect Down syndrome, an amniocentesis will also 
detect other chromosomal abnormalities or neural tube defects, which are birth defects of the 
spine, spinal cord, and brain.   
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minute Apgar score is less than seven, actually increase at the amniocentesis eligibility cutoff.  
(While statistically significant, it is important to note that these coefficients are quite small  
relative to the mean, so the reader should be cautious in her interpretation of the economic 
significance of these point estimates.)  
 
Table 6, The Effect of Amniocentesis Eligibility on Broader Indicators of Infant Health, 
All Years (1989-2002 Combined) 
The regressions in all columns were estimated using a bandwidth of two (i.e., only women ages 33 to 37 (inclusive) 
were included in the sample). AMA is an indicator variable that equals one if the mother was at least age 35 at the 
birth of her child, and a child was considered to have a chromosomal abnormality and/or neural tube defect if Down 
syndrome, anencephaly, spina bifida/meningocele, and/or “other chromosomal abnormality” was reported on the 
child’s birth certificate. Each regression controls for the mother and father’s race and ethnicity, the mother’s 
educational attainment, the mother’s marital status, and the father’s age. Standard errors are clustered by mother’s 
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Child is Born at 
a Very Low 
Birth Weight 
(<1,500 grams) 
      
AMA 0.00010* -0.00573** 0.00113*** 0.00206*** 0.00007 
 (0.00004) (0.00078) (0.00000) (0.00022) (0.00018) 
Age – 35  0.00005*** -0.00351*** 0.00011** 0.00269*** 0.00092*** 
 (0.00001) (0.00012) (0.00003) (0.00005) (0.00001) 
(Age – 35)*AMA 0.00012** -0.00413*** 0.00023*** 0.00129*** 0.00031 
 (0.00003) (0.00069) (0.00000) (0.00019) (0.00016) 
Constant 0.00162*** 8.85835*** 0.01999*** 0.08932*** 0.02103*** 
 (0.00032) (0.00748) (0.00141) (0.00255) (0.00056) 
Controls Yes Yes Yes Yes Yes 
Mean of Dependent Variable 0.0011 8.8830 0.0135 0.0739 0.0185 
N 1,300,488 1,300,488 1,300,488 1,300,488 1,300,488 
R2 0.00006 0.00129 0.00106 0.00358 0.00308 
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Section 7: Robustness Checks and Falsification Tests 
 
To ensure that the results presented above were not sensitive to my choice of bandwidth, 
I re-estimated equations (1) and (2) for the combined period of 1989-2002 with an assortment of 
different bandwidths. Reassuringly, my results are qualitatively consistent with a variety of 
bandwidths, from three to ten, and these alternative results are given in Tables 7 and 8.14  
As an additional robustness check, I implemented a series of falsification tests, where I 
estimated equation (1), but instead of placing the amniocentesis eligibility cutoff at 35, I placed 
the amniocentesis eligibility cutoff at each maternal age from 20 to 43. Considering that the 
amniocentesis eligibility cutoff is located at age 35, the #$’s at maternal ages other than 35 
should be close to zero and statistically insignificant. A graph of the estimated coefficients from 
these falsification tests is given in Figure 11.  
As Figure 11 clearly demonstrates, the #$’s from the regressions implemented with these 
fake amniocentesis eligibility cutoffs hovered close to zero, with the exception of the #$ on 36. 
Importantly, however, the apparent drop in amniocentesis take-up at 36 can be explained by the 
fact that the actual amniocentesis eligibility cutoff is located at age 35, the maternal age 
immediately before 36. Since there was a sharp increase in amniocentesis take-up at age 35 (see 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
14 While qualitatively consistent with the results provided in Table 2, the results depicted in 
Table 10 show that as the bandwidth increases, the magnitude of the point estimate on AMA 
increases. This seemingly odd result is due to several factors. First, a line is an increasingly poor 
fit for the underlying relationship between maternal age and amniocentesis take-up as more ages 
are included in the sample, biasing the estimated coefficient on AMA. Second, while the slope of 
the regression line on the right-hand side of the cutoff is roughly the same across all bandwidths, 
the slope of the regression line on the left-hand side of the cutoff becomes noticeably shallower 
as the bandwidth increases. This combination of a shallower slope on the left-hand side of the 
cutoff—which is driven by the inclusion of more and more non-AMA women who did not 
undergo an amniocentesis into the sample—with a stable slope on the right hand side of the 
cutoff, pushes the point estimate on AMA upwards as the bandwidth increases. 
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Table 2), and equation (1) allows the slopes of the regression lines to be different on either side 
of the eligibility cutoff, the #$ on 36 is negative (and nearly equal to magnitude to the #$ on 35) 
because the actual change in amniocentesis take-up at 36 is far less than what the change in 
amniocentesis take-up at 36 should have been if amniocentesis take-up had continued to increase 
at the rate it did from age 34 to age 35. In other words, the #$ on 36 is consistent with what I 
would expect to see, assuming that the only discontinuity in amniocentesis take-up was located 













Table 7 The Effect of Amniocentesis Eligibility on Amniocentesis Take-up (All Years 1989-2002 Combined), 
Estimated Separately for Bandwidth=2 to Bandwidth=10 
The dependent variable is an indicator variable that equals one if the mother underwent an amniocentesis. Column one corresponds to an estimation of equation 
(1) with a bandwidth of two, column two corresponds to an estimation of equation (1) with a bandwidth of three, etc. AMA is an indicator variable that equals 
one if the mother was at least age 35 at the birth of her child. Standard errors are clustered by mother’s age, and standard errors are given in parentheses. 
*p < 0.10, **p < 0.05, ***p < 0.01 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
 BW=2 BW=3 BW=4 BW=5 BW=6 BW=7 BW=8 BW=9 BW=10 
          
AMA 0.0617*** 0.0755*** 0.0841*** 0.0907*** 0.0961*** 0.1010*** 0.1054*** 0.1091*** 0.1123*** 
 (0.0018) (0.0065) (0.0086) (0.0091) (0.0091) (0.0090) (0.0090) (0.0090) (0.0089) 
Age – 35  0.0228*** 0.0140*** 0.0098*** 0.0073*** 0.0057*** 0.0045*** 0.0037*** 0.0030*** 0.0025*** 
 (0.0001) (0.0021) (0.0023) (0.0020) (0.0017) (0.0014) (0.0012) (0.0010) (0.0009) 
(Age – 35)*AMA -0.0019 0.0041 0.0069** 0.0088*** 0.0096*** 0.0099*** 0.0101*** 0.0101*** 0.0101*** 
 (0.0015) (0.0027) (0.0027) (0.0024) (0.0021) (0.0020) (0.0020) (0.0019) (0.0019) 
Non-white Mother -0.0123** -0.0109** -0.0095** -0.0085** -0.0076*** -0.0066*** -0.0059*** -0.0052*** -0.0048*** 
 (0.0044) (0.0040) (0.0034) (0.0029) (0.0025) (0.0022) (0.0019) (0.0017) (0.0015) 
Hispanic Mother -0.0176** -0.0160** -0.0136** -0.0119*** -0.0103*** -0.0089*** -0.0079*** -0.0069*** -0.0062*** 
 (0.0057) (0.0048) (0.0042) (0.0036) (0.0031) (0.0026) (0.0022) (0.0019) (0.0016) 
Mother Did Not Complete High School -0.0238* -0.0205** -0.0180** -0.0156** -0.0134** -0.0116** -0.0096** -0.0078** -0.0065*** 
 (0.0095) (0.0079) (0.0068) (0.0059) (0.0050) (0.0041) (0.0034) (0.0028) (0.0023) 
Mother Completed Some College 0.0134** 0.0114** 0.0097** 0.0084** 0.0071** 0.0061** 0.0052** 0.0043** 0.0037** 
 (0.0047) (0.0041) (0.0035) (0.0030) (0.0026) (0.0022) (0.0019) (0.0016) (0.0014) 
Mother Graduated College 0.0337** 0.0285** 0.0243** 0.0207** 0.0175** 0.0150** 0.0128** 0.0110** 0.0096** 
 (0.0093) (0.0085) (0.0076) (0.0067) (0.0058) (0.0051) (0.0045) (0.0040) (0.0036) 
Mother is Married -0.0057*** -0.0055*** -0.0052*** -0.0047*** -0.0044*** -0.0042*** -0.0040*** -0.0038*** -0.0036*** 
 (0.0009) (0.0013) (0.0013) (0.0012) (0.0011) (0.0011) (0.0010) (0.0010) (0.0010) 
Father’s Age 0.0011*** 0.0010*** 0.0009*** 0.0008*** 0.0007*** 0.0007*** 0.0006*** 0.0006*** 0.0005*** 
 (0.0002) (0.0002) (0.0002) (0.0002) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
Non-white Father -0.0195** -0.0168** -0.0144** -0.0120** -0.0103** -0.0090** -0.0080*** -0.0072*** -0.0064*** 
 (0.0053) (0.0048) (0.0044) (0.0040) (0.0036) (0.0031) (0.0027) (0.0024) (0.0022) 
Hispanic Father -0.0178** -0.0153** -0.0137** -0.0114** -0.0098*** -0.0083*** -0.0071*** -0.0064*** -0.0057*** 
 (0.0053) (0.0050) (0.0043) (0.0037) (0.0031) (0.0025) (0.0021) (0.0017) (0.0015) 
Constant 0.0326** 0.0275** 0.0246** 0.0229** 0.0224** 0.0218** 0.0210** 0.0203** 0.0197*** 
 (0.0088) (0.0078) (0.0086) (0.0087) (0.0084) (0.0080) (0.0076) (0.0072) (0.0069) 
          
Mean of Dependent Variable 0.0258 0.0258 0.0258 0.0258 0.0258 0.0258 0.0258 0.0258 0.0258 
N 1,679,707 2,430,930 3,272,574 4,208,341 5,209,431 6,247,423 7,297,430 8,334,741 9,342,971 
R2 0.0462 0.0579 0.0672 0.0740 0.0784 0.0806 0.0813 0.0810 0.0804 
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Table 8, The Effect of Amniocentesis Eligibility on Down syndrome Incidence (All Years 1989-2002 Combined), 
Estimated Separately for Bandwidth=2 to Bandwidth=10 
The dependent variable is an indicator variable that equals one if the mother underwent an amniocentesis. Column one corresponds to an estimation of equation 
(1) with a bandwidth of two, column two corresponds to an estimation of equation (1) with a bandwidth of three, etc. AMA is an indicator variable that equals 
one if the mother was at least age 35 at the birth of her child. Standard errors are clustered by mother’s age, and standard errors are given in parentheses.  
*p < 0.10, **p < 0.05, ***p < 0.01 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
 BW=2 BW=3 BW=4 BW=5 BW=6 BW=7 BW=8 BW=9 BW=10 
          
AMA 0.00004 0.00000 -0.00008 -0.00007 -0.00005 -0.00005 -0.00003 -0.00004 -0.00003 
 (0.00002) (0.00005) (0.00008) (0.00007) (0.00008) (0.00009) (0.00009) (0.00010) (0.00010) 
Age – 35  0.00004*** 0.00005*** 0.00007*** 0.00006*** 0.00005*** 0.00004*** 0.00004*** 0.00003*** 0.00003*** 
 (0.00000) (0.00000) (0.00001) (0.00001) (0.00001) (0.00001) (0.00001) (0.00001) (0.00001) 
(Age – 35)*AMA 0.00003 0.00007* 0.00009** 0.00011*** 0.00014*** 0.00016*** 0.00017*** 0.00019*** 0.00019*** 
 (0.00002) (0.00003) (0.00004) (0.00003) (0.00003) (0.00002) (0.00002) (0.00003) (0.00003) 
Non-white Mother -0.00015* -0.00024** -0.00026*** -0.00021*** -0.00020*** -0.00019*** -0.00018*** -0.00016*** -0.00016*** 
 (0.00006) (0.00007) (0.00006) (0.00006) (0.00005) (0.00004) (0.00004) (0.00004) (0.00003) 
Hispanic Mother -0.00019 -0.00010 -0.00008 -0.00007 -0.00008 -0.00007 -0.00006 -0.00004 -0.00003 
 (0.00016) (0.00013) (0.00010) (0.00008) (0.00007) (0.00006) (0.00005) (0.00005) (0.00004) 
Mother Did Not Complete High School 0.00002 0.00001 -0.00007 -0.00007 -0.00004 -0.00003 -0.00000 -0.00001 -0.00002 
 (0.00007) (0.00005) (0.00007) (0.00005) (0.00005) (0.00004) (0.00004) (0.00004) (0.00003) 
Mother Completed Some College -0.00010 -0.00010** -0.00009** -0.00009*** -0.00009*** -0.00008*** -0.00006** -0.00003 -0.00003 
 (0.00005) (0.00004) (0.00003) (0.00002) (0.00002) (0.00002) (0.00002) (0.00003) (0.00003) 
Mother Graduated College -0.00021** -0.00016** -0.00016** -0.00014*** -0.00014*** -0.00012*** -0.00010*** -0.00008** -0.00007** 
 (0.00007) (0.00006) (0.00005) (0.00004) (0.00003) (0.00004) (0.00003) (0.00003) (0.00003) 
Mother is Married 0.00002 0.00004 0.00005 0.00005 0.00005 0.00005* 0.00005** 0.00003 0.00003 
 (0.00008) (0.00006) (0.00005) (0.00004) (0.00003) (0.00003) (0.00002) (0.00002) (0.00002) 
Father’s Age -0.00001 -0.00001 -0.00001 -0.00001* -0.00000* -0.00000** -0.00000* -0.00000** -0.00000** 
 (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) 
Non-white Father -0.00016 -0.00008 -0.00005 -0.00009 -0.00008 -0.00006 -0.00006 -0.00008* -0.00006 
 (0.00008) (0.00008) (0.00006) (0.00006) (0.00005) (0.00005) (0.00004) (0.00004) (0.00004) 
Hispanic Father -0.00012 -0.00007 -0.00001 0.00000 -0.00001 -0.00003 -0.00004 -0.00005 -0.00005 
 (0.00010) (0.00007) (0.00007) (0.00006) (0.00005) (0.00004) (0.00004) (0.00004) (0.00003) 
Constant 0.00103*** 0.00097*** 0.00097*** 0.00091*** 0.00085*** 0.00082*** 0.00075*** 0.00074*** 0.00072*** 
 (0.00011) (0.00015) (0.00012) (0.00011) (0.00011) (0.00010) (0.00011) (0.00010) (0.00009) 
          
Mean of Dependent Variable 0.00036 0.00036 0.00036 0.00036 0.00036 0.00036 0.00036 0.00036 0.00036 
N 1,606,152 2,325,058 3,130,853 4,027,065 4,986,486 5,981,891 6,989,279 7,985,800 8,955,580 




Notes: The purple bands around each point estimate are 95% confidence intervals. The point estimate given in blue is equal to the estimated coefficient on AMA in Column 2 of 







































Maternal Age Amniocentesis "Eligibility Cutoff"
The Effect of Amniocentesis "Eligibility" on Amniocentesis Take-Up, with Fake Amniocentesis Eligibility Cutoffs 
(All Years, 1989-2002 Combined) 
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Section 8: Conclusion 
 
My investigation of the effect of women’s access to prenatal genetic testing for Down 
syndrome on test utilization and corresponding birth outcomes reveals three key results. First, I 
find that becoming eligible for an amniocentesis—the most common diagnostic test for Down 
syndrome—had a significant impact on women’s prenatal genetic testing decisions. Over the 
period from 1989 to 2002, I find that the probability that a woman underwent an amniocentesis 
increased by 6.17 percentage points at age 35, the location of the amniocentesis eligibility 
threshold. While this increase may seem small when viewed out of context, this 6.17 percentage 
point increase translates to a 62% increase over the mean amniocentesis take-up rate in my 
preferred sample (which consists only of first-time mothers age 33 to 37), and to a staggering 
239% increase over the mean amniocentesis take-up rate for my full sample of first-time 
mothers.   
Second, I find that the increase in amniocentesis take-up at age 35 decreased substantially 
over the course of 1989 to 2002. Given that the 1990s were marked by the introduction of 
prenatal screening tests for Down syndrome—which, unlike an amniocentesis, presented 
essentially zero risk to the fetus—this clear downward trend in amniocentesis take-up at age 35 
implies that many women at the amniocentesis eligibility threshold were substituting away from 
amniocentesis, and choosing instead to rely only on the results of prenatal screening tests for 
Down syndrome. Even though these prenatal screenings tests are less accurate than an 
amniocentesis—prenatal screening tests can only estimate the likelihood that the fetus has Down 
syndrome—the strong downward time trend in amniocentesis take-up at age 35 suggests that 
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many women at the amniocentesis eligibility threshold were willing to accept this increased 
uncertainty in order to minimize the risk presented to the fetus.  
Third, despite the clear increase in amniocentesis take-up at age 35, I find no evidence 
that women acted on the results provided by an amniocentesis. I find no evidence of a decrease 
in Down syndrome incidence at the amniocentesis eligibility threshold (which would be 
consistent with women terminating pregnancies in which the fetus tested positive for Down 
syndrome), and I also find no improvements along other broader measures of infant health, such 
as birth weight and the infant’s five-minute Apgar score.15 
It is possible, however, that AMA women benefited from an amniocentesis in ways that 
are unobservable in the Vital Statistics data. That is, rather than using the results of an 
amniocentesis to decide whether to terminate the pregnancy, parents may have utilized the 
results of an amniocentesis to better prepare for the type of care their child would need during 
and after birth. For example, parents who learned that their child has Down syndrome may have 
enrolled in support groups, restructured their health insurance plans to accommodate the types of 
health care services their child would eventually need, or moved closer to relatives or friends 
who would be able to help provide care. 
While these are certainly important ways in which AMA women could have benefited 
from an amniocentesis, the fact that I find no evidence that women terminated pregnancies that 
tested positive for Down syndrome—combined with the fact that amniocentesis take-up was far 
less than 100% at the AMA threshold—leads me to question whether 35 was, in fact, the optimal 
location for the amniocentesis eligibility cutoff. In 1978, when no prenatal screening tests for 
Down syndrome were available, the NIH’s placement of the amniocentesis eligibility cutoff at 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
15 It is important to acknowledge, however, that these results may be partially driven by low 
statistical power. 
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age 35 seemed logical: While imperfect, maternal age is a reasonable proxy for the likelihood 
that the fetus will have Down syndrome, and Down syndrome risk does begin to increase 
substantially once a woman reaches about 30 years old (see Figure 4).  
By placing the amniocentesis eligibility cutoff at age 35, however, the NIH may have 
unwittingly restricted amniocentesis access to women who were the least incentivized to both 
undergo and act upon an amniocentesis. Raising a child with Down syndrome carries heavy 
pecuniary and non-pecuniary costs: Health care costs for children with Down syndrome are 
roughly 12 times higher than those of a typical child, and children with Down syndrome 
generally require around-the-clock care, which can take a large emotional toll on the child’s 
entire family (Boulet, et al., 2008). AMA women—and in particular, AMA women expecting 
their first child—may simply be more willing to shoulder these costs, since it is uncertain 
when—or even if—they could “replace” an amniocentesis-caused miscarriage or intentionally-
terminated pregnancy. My results, which (1) show a fairly small effect of amniocentesis 
eligibility on take-up in absolute terms, and (2) provide no evidence that AMA women 
terminated pregnancies that tested positive for Down syndrome, are broadly consistent with this 
story.  
Younger (non-AMA) women may be less willing—or even unable—to absorb these 
costs, and thus may have a differentially greater incentive to undergo an amniocentesis and 
terminate pregnancies that test positive for Down syndrome. In this case, then, the informational 
value of an amniocentesis is likely higher for younger, non-AMA women. If the NIH’s goal was 
to place the amniocentesis eligibility cutoff at an age where the value of the informational 
content from an amniocentesis was highest, perhaps the cutoff should have been located at a 
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younger age, particularly when amniocentesis was the only available prenatal genetic test for 
Down syndrome.  
Of course, the argument for placing the amniocentesis eligibility cutoff at a younger age 
is grounded in the assumption that women are rational actors, or that women would choose to 
undergo an amniocentesis only if the benefits exceeded the costs. If this is not the case, and 
instead, women blindly follow their doctor’s prenatal genetic testing recommendations, then 
lowering the amniocentesis eligibility cutoff would potentially have had significant negative 
ramifications. In this scenario, thousands of additional women would likely have undergone an 
uncomfortable and expensive procedure that provided them little to no benefit.  
In the coming years and decades, genetic tests will likely become an increasingly 
important part of our lives. It is unclear, however, to what extent my results can be extrapolated 
to other settings. In other contexts, individuals may not have the option between screening and 
diagnostic tests, and the benefits of undergoing a genetic test may differ depending on whether 
the test reveals information about a fetus (like prenatal genetic testing for Down syndrome) or 
about the individual herself (like genetic testing for Huntingdon’s disease). Moreover, Down 
syndrome is an “untreatable” genetic condition, meaning that a woman’s incentives to undergo 
prenatal genetic testing for Down syndrome may be quite different, for example, than her 
incentives to undergo a genetic test that can detect mutations in the two known breast cancer 
genes (BRCA 1 and BRCA 2). Unlike prenatal genetic testing for Down syndrome, if a woman 
receives a positive result on her BRCA gene test, she can actually take preventative measures to 
minimize her risk of developing breast cancer. As scientists continue to develop a better 
understanding of the human genome, individuals will likely face a host of difficult genetic 
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testing decisions like those outlined above, and these decisions—which can have large 
consequences for the healthcare system—deserve the attention of future research.  
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Mother is Hispanic 
(3) 
Mother is Married  
(4) 









 AMA -0.00574*** 0.00038 -0.00007 0.00006 -0.00156** 0.00148* 
 (0.00026) (0.00025) (0.00005) (0.00019) (0.00033) (0.00051) 
Age-35 0.00197*** -0.00137*** -0.00340*** -0.00021*** 0.00042*** -0.00031*** 
 (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) 
(Age-35)*AMA -0.00083* 0.00116** -0.00228*** 0.00100** -0.00176** -0.00046 
 (0.00023) (0.00022) (0.00005) (0.00017) (0.00028) (0.00044) 
Constant 0.15439*** 0.07854*** 0.91932*** 0.03083*** 0.19322*** 0.22038*** 
 (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) 
       
Mean of Dependent Variable 0.1626 0.0860 0.8672 0.0387 0.2029 0.2219 
N  1,635,188 1,635,188 1,635,188 1,635,188 1,635,188 1,635,188 
R2 0.00001 0.00002 0.00049 0.00001 0.00001 0.00000 



















Father is Non-White 
AMA 0.00002 -0.00112** 0.00048 0.00053*** 0.00397*** -0.00567*** 
 (0.001) (0.00017) (0.00020) (0.00005) (0.00019) (0.00015) 
Age-35 0.00010*** -0.00031*** 0.00037*** -0.00013*** 0.00158*** 0.00166*** 
 (0.000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) 
(Age-35)*AMA 0.00122 -0.00011 -0.00007 0.00002 -0.00165*** -0.00102** 
 (0.001) (0.00015) (0.00018) (0.00004) (0.00016) (0.00013) 
Constant 0.55557*** 0.93765*** 0.05073*** 0.00844*** 0.64893*** 0.14592*** 
 (0.000) (0.00000) (0.00000) (0.00000) (0.00000) (0.00000) 
       
Mean of Dependent Variable 0.5365 0.9280 0.0585 0.0111 0.6443 0.1437 
N  1,635,188 1,635,188 1,635,188 1,635,188 1,635,188 1,635,188 
R2 0.00000 0.00002 0.00001 0.00000 0.00005 0.00002 
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The dependent variable is given in the column title. The regressions in both columns were estimated using a bandwidth of two (i.e., only women ages 33 to 37 
(inclusive) were included in the sample). AMA is an indicator variable that equals one if the mother was at least age 35 at the birth of her child. Standard errors 
are clustered by mother’s age, and standard errors are given in parentheses. *p < 0.10, **p < 0.05, ***p < 0.01. 
Dependent Variable: (13) 










Mean of Dependent Variable 0.0751 
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